Drug intelligence / Profile preview

CUR201

Development stage: Preclinical
Lead developer: Curamys
Modality: RNA Therapeutics → Nucleic Acid Therapeutics

Overview

CUR201 is a microRNA (miRNA) therapeutic candidate currently in the discovery phase for the treatment of Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease. Developed by Curamys, the drug is designed to target specific disease-associated microRNAs that are implicated in the pathogenesis of ALS. By modulating the levels of these regulatory RNA molecules, CUR201 aims to address the underlying molecular mechanisms of neurodegeneration. The program is part of a broader pipeline at Curamys focused on utilizing miRNA technology to treat neuromuscular and neurodegenerative disorders.

Beyond the preview

Go deeper on CUR201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CUR201.

Explore the full profile